HIGHLIGHT
Ryzodeg FlexTouch

Ryzodeg FlexTouch

Manufacturer:

Novo Nordisk

Distributor:

Zuellig Pharma

Marketer:

Novo Nordisk
Concise Prescribing Info
Contents
Per mL Insulin degludec 70% (equiv to 2.56 mg), insulin aspart 30% (equiv to 1.05 mg)
Indications/Uses
DM in adults, adolescents & childn ≥2 yr.
Dosage/Direction for Use
SC Individualized dosage. Once daily or bid w/ main meals. Patients w/ type 2 DM Recommended total daily starting dose: 10 U w/ meal(s) followed by individual dosage adjustments. May be administered alone, in combination w/ oral antidiabetics & bolus insulin. Patients w/ type 1 DM Recommended starting dose: 60-70% of total daily insulin requirements once daily at meal time in combination w/ short- or rapid-acting insulin at the remaining meals followed by individual dosage adjustments.
Administration
Should be taken with food.
Special Precautions
Not to be administered IV or IM. Not to be used in insulin infusion pumps. Hypo-/hyperglycaemia. Concomitant illness especially infection & fever; adrenal, pituitary or thyroid gland diseases. Temporary worsening of diabetic retinopathy due to intensification of insulin therapy w/ abrupt improvement in glycaemic control. Omission of meal or unplanned strenuous physical exercise; inadequate dosing &/or discontinuation of treatment. May cause insulin Ab formation. Transferring from other insulin medicinal products. Combination w/ thiazolidinediones. May affect ability to drive & use machines. Renal or hepatic impairment. Pregnancy & lactation. Higher risk for severe hypoglycaemia in childn 2-5 yr.
Adverse Reactions
Drug Interactions
May reduce insulin requirement w/ oral antidiabetics, GLP-1 receptor agonists, MAOIs, β-blockers, ACE inhibitors, salicylates, anabolic steroids & sulfonamides. May increase insulin requirement w/ OCs, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone & danazol. Symptoms of hypoglycaemia may be masked by β-blockers. May either increase or decrease insulin requirement w/ octreotide/lanreotide. Hypoglycemic effect may be intensified or reduced by alcohol.
ATC Classification
A10AD06 - insulin degludec and insulin aspart ; Belongs to the class of intermediate-acting combined with fast-acting insulins and analogues. Used in the treatment of diabetes.
Presentation/Packing
Form
Ryzodeg FlexTouch soln for inj 100 IU/mL
Packing/Price
3 mL x 5 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in